Primacor Side Effects
Generic Name: milrinone
Note: This document contains side effect information about milrinone. Some of the dosage forms listed on this page may not apply to the brand name Primacor.
For the Consumer
Applies to milrinone: parenteral injection for iv infusion, parenteral injection for iv use
Side effects include:
For Healthcare Professionals
Applies to milrinone: intravenous solution
Cardiovascular side effects have included ventricular arrhythmias (12%), ventricular ectopic activity (8%), supraventricular arrhythmias (3.8%), sustained and nonsustained ventricular tachycardia (1% and 2.8%, respectively), ventricular fibrillation (0.2%), and atrial fibrillation. Hypotension (2.9%) and angina/chest pain (1.2%) have occurred. In addition, rare reports of torsades de pointes have been reported in postmarketing experience.[Ref]
Hematologic side effects of reversible thrombocytopenia (0.4%), inhibition of platelet activity, and increased bleeding time have occurred. While these effects have been described in patients undergoing cardiac surgery who had received milrinone (the active ingredient contained in Primacor) for 12 to 24 hours, they have not been associated with acute administration of milrinone. The hematologic side effects of milrinone may be important in some patients who are awaiting cardiac catheterization, transplant, or other significant invasive procedures.[Ref]
Milrinone has been shown to inhibit human platelet thromboxane A2 synthesis and calcium uptake.[Ref]
General gastrointestinal complaints have been reported rarely.[Ref]
Hepatic side effects including liver function test abnormalities have been reported in postmarketing experience.[Ref]
Other side effects including rash and skin reactions have been reported in postmarketing experience.[Ref]
Respiratory side effects have been reported including isolated, spontaneous reports of bronchospasm.[Ref]
Dermatologic side effects including rash has been reported in postmarketing experience.
Local side effects including infusion site reaction has been reported in postmarketing experience.
1. Mehra MR, Ventura HO, Kapoor C, Stapleton DD, Zimmerman D, Smart FW "Safety and clinical utility of long-term intravenous Milrinone in advanced heart failure." Am J Cardiol 80 (1997): 61-4
2. Fleming GA, Murray KT, Yu C, et al. "Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery." Circulation 118 (2008): 1619-25
3. "Product Information. Primacor (milrinone)." Sanofi Winthrop Pharmaceuticals, New York, NY.
4. MilfredLaforest SK, Shubert J, Mendoza B, Flores I, Eisen HJ, Pina IL "Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors." Am J Cardiol 84 (1999): 894-9
5. Packer M, Carver JR, Rodeheffer RJ, et al "Effect of oral milrinone of mortality in severe chronic heart failure." N Engl J Med 325 (1991): 1468-75
6. Jeremy JY, Gill J, Mikhailidis D "Effect of milrinone on thromboxane A2 synthesis, cAMP phosphodiesterase and 45Ca2+ uptake by human platelets." Eur J Pharmacol 245 (1993): 67-73
7. Kikura M, Lee MK, Safon RA, Bailey JM, Levy JH "The effects of milrinone on platelets in patients undergoing cardiac surgery." Anesth Analg 81 (1995): 44-8
8. Hasegawa R "Milrinone, a new agent for the treatment of congestive heart failure." Clin Pharm 5 (1986): 201-5
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.